|Drug, bio-affecting and body treating compositions patents - Monitor Patents|
USPTO Class 424 | Browse by Industry: Previous - Next | All
Recent | 14: | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | 13: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | 12: Dec | Nov | Oct | Sep | Aug | July | June | May | April | Mar | Feb | Jan | 11: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | 10: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | | 09: Dec | Nov | Oct | Sep | Aug | Jl | Jn | May | Apr | Mar | Fb | Jn | | 2008 | 2007 |
Drug, bio-affecting and body treating compositionsBelow are recently published patent applications awaiting approval from the USPTO. Recent week's RSS XML file available below.
Listing for abstract view: USPTO application #, Title, Abstract excerpt,Patent Agent. Listing format for list view: USPTO National Class full category number, title of the patent application. 11/13/2014 > 198 patent applications in 107 patent subcategories.
20140335014 - Il-1 alpha dual variable domain immunoglobulins and uses thereof: The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease.... Agent: Abbvie, Inc.
20140335015 - Nanoparticles comprising metallic and hafnium oxide materials, preparation and uses thereof: The present invention relates to novel nanoparticles which can be advantageously used in the health sector as diagnostic and/or therapeutic agents. Nanoparticles of the invention comprise a metallic material at least partly covered with an hafnium oxide material or embedded therein. When compared to existing products, these nanoparticles offer a... Agent:
20140335016 - Bacteriophage gene 3 protein compositions and use as amyloid binding agents: The invention relates to agents and to pharmaceutical compositions for reducing the formation of amyloid and/or for promoting the disaggregation of amyloid proteins. The compositions may also be used to detect amyloid.... Agent: Neurophage Pharmaceuticals, Inc.
20140335017 - Strontium phosphate microparticle for radiological imaging and therapy: This invention relates to strontium-phosphate microparticles that incorporate radioisotopes for radiation therapy and imaging.... Agent:
20140335018 - Pharmaceutical composition comprising modified hemoglobin-based therapeutic agent for cancer targeting treatment and diagnostic imaging: The present invention provides a pharmaceutical composition containing hemoglobin-based therapeutic agent for treating cancer. The hemoglobin moiety can target cancer cells and the therapeutic moiety (i.e. active agent/therapeutic drug) can kill the cancer cells efficiently. The hemoglobin-based therapeutic agent used in the present invention can be used in the treatment... Agent: Vision Global Holdings Ltd.
20140335019 - Compositions and methods for the treatment and analysis of neurological disorders: Provided herein are compositions and methods for the treatment and analysis of neurological disorders. In particular, provided herein are small molecules targeted to amyloid-β (Aβ) or metal-Aβ species for the treatment, diagnosis, or study of neurological conditions such as Alzheimer's disease (AD) and other diseases and conditions.... Agent:
20140335020 - Composition and method of making the novel polymer gel for use in dosimeter: Normal N-(Hydroxymethyl) acrylamide (PNHMAG) and normoxic N-(Hydroxymethyl) acrylamide (NHMAGAT) polymer gel dosimeters with low toxicity and low cost are invented for radiation treatment planning. A high dose response was displayed in this invention using nuclear magnetic resonance (NMR) and spectrophotometer methods. The response of both types of gels showed an... Agent:
20140335022 - Method for patient selection: The present invention relates to methods useful in the selection of cancer patients suitable for treatment with therapies directed at c-Met. The method employs imaging agents which comprise 18F-radiolabelled c-Met binding peptides suitable for positron emission tomography (PET) imaging in vivo. Also disclosed are methods of treatment, methods of monitoring... Agent:
20140335021 - Ocular neostigmine drops for diagnosing myasthenia gravis: Disclosed is a method for aiding in the diagnosis of myasthenia gravis. Neostigmine, for example one drop of standard intravenous neostigmine solution (2.5 mg/ml) is instilled into each symptomatic or ptotic eye of patients with suspected or probable myasthenia gravis. The patient is later evaluated for possible changes in ptosis.... Agent:
20140335023 - Plasma kallikrein binding proteins: Plasma kallikrein binding proteins and methods of using such proteins are described.... Agent: Dyax Corp.
20140335025 - Targeting corroles for tumor toxicity and mri: Disclosed herein are compositions comprising a targeted corrole nanoparticle; and an acceptable excipient. Also disclosed are compositions comprising a targeted corrole nanoparticle; and an acceptable carrier. Further, disclosed herein are methods of imaging a condition in a subject, comprising providing a composition comprising a targeted corrole nanoparticle; administering an effective... Agent: Cedars-sinai Medical Center
20140335024 - Nanocarriers for imaging and therapy applications: Nanocarriers and methods of preparation and use of nanocarriers are presented. In some embodiments, a nanocarrier composition comprises an organic liquid comprising a plurality of nanoparticles dispersed therein; and a coating material disposed around the exterior surface of the organic liquid. Biological tissue may be imaged or treated by coming... Agent:
20140335027 - Heatiness and salivary secretory immunoglobulin: Described herein are methods of assessing the severity of heatiness in a patient, comprising measuring salivary S-IgA levels, which are found to correlate negatively with the degree of heatiness. The invention further provides, i.a., diagnostic kits, methods of treatment, and the use of oral care compositions to treat heatiness.... Agent: Colgate-palmolive Company
20140335026 - Method of cleaning an oral appliance: A method of cleaning an oral appliance allows a dental patient or other oral appliance wearer to clean the appliance while the appliance is in place in the wearer's mouth. The appliance wearer dispenses a quantity of foamed, cleanser formulation into to his or her mouth, swishes the cleanser around... Agent:
20140335028 - Hydrophobic tooth whitening system and methods of use: A tooth whitening system comprising a dental tray having a surface operable to confront a tooth surface, and a tooth whitening composition comprising a whitening agent and a hydrophobic polymer carrier. The tooth whitening composition is preferably substantially non-water soluble. A tooth whitening kit is also provided using a dental... Agent:
20140335029 - Use of cyclohexanol derivatives as antimicrobial active compounds: The present invention relates to the use of at least one cyclohexanol derivative of the formula (I) and/or (II) as antimicrobial active compound or as anti-acne, antidandruff, antiperspirant or deodorant active compound, to preparations comprising these compounds, and to specific cyclohexanol derivatives and to a process for the preparation thereof.... Agent: Merck Patent Gmbh
20140335031 - Liquid solution comprising peba: A liquid composition including between 1 and 15 parts by weight of PEBA to 100 parts by weight of solvent, wherein: said solvent includes between 1 and 49% by volume of alcohol low in C1 to C4 and between 51 and 99% by volume of a cosolvent miscible with alcohol,... Agent:
20140335030 - Modular emulsion-based product differentiation: A micro-scale heterogeneous emulsion is provided. In some examples, the micro-scale heterogeneous emulsion can include at least two internal phases and an external phase. A method of producing a micro-scale heterogeneous emulsion is also disclosed herein. A method of providing a stable, custom cosmetic composition is also disclosed herein.... Agent: The Procter & Gamble Company
20140335032 - Consumer products comprising silane-modified oils: A consumer product comprises silane-modified oil comprising a hydrocarbon chain selected from the group consisting of: a saturated oil, an unsaturated oil, and mixtures thereof; and at least one hydrolysable silyl group covalently bonded to the hydrocarbon chain. The consumer product further comprises a hydroxyl functional organic species and is... Agent: The Procter & Gamble Company
20140335033 - Consumer products comprising silane-modified oils: A consumer product comprises silane-modified oil comprising a hydrocarbon chain selected from the group consisting of: a saturated oil, an unsaturated oil, and mixtures thereof; and at least one hydrolysable silyl group covalently bonded to the hydrocarbon chain. The consumer product further comprises a perfume.... Agent: The Procter & Gamble Company
20140335034 - Consumer products comprising silane-modified oils: A consumer product comprises silane-modified oil comprising a hydrocarbon chain selected from the group consisting of: a saturated oil, an unsaturated oil, and mixtures thereof; and at least one hydrolysable silyl group covalently bonded to the hydrocarbon chain. The consumer product further comprises a preservative.... Agent: The Procter & Gamble Company
20140335035 - Consumer products comprising silane-modified oils: A consumer product comprises silane-modified oil comprising a hydrocarbon chain selected from the group consisting of: a saturated oil, an unsaturated oil, and mixtures thereof; and at least one hydrolysable silyl group covalently bonded to the hydrocarbon chain. The consumer product further comprises a particulate benefit agent.... Agent: The Procter & Gamble Company
20140335037 - Aqueous oxidizing composition: Present invention relates to an aqueous oxidizing composition comprising at least one oxidizing, at least one alkyl or alkanol amine, urea, at least one carbonate salt and at least one natural triglyceride. Composition comprises furthermore hair dyes.... Agent:
20140335036 - Hair care conditioning composition comprising histidine: A hair care composition having from about from about 0.025% to about 0.25% by weight of the composition of histidine. The hair care composition further includes a gel matrix phase. The gel matrix has from about 0.1% to about 20% of one or more high melting point fatty compounds, from... Agent: The Procter & Gamble Company
20140335042 - Hair care composition comprising silicone grafted starch: A hair care composition having from about 0.05% to about 15% of silicone grafted tapioca starch. The hair care composition further includes a gel matrix phase. The gel matrix has from about 0.1% to about 20% of one or more high melting point fatty compounds, from about 0.1% to about... Agent: The Procter & Gamble Company
20140335041 - Shampoo compositions and methods of making same: The present invention relates to a shampoo composition and methods of using the same. The shampoo composition includes a silicone grafted tapioca starch, a detersive surfactant, a cationic conditioning polymer, and a carrier. The shampoo composition can provide both conditioning and volume benefits.... Agent: The Procter & Gamble Company
20140335038 - Method of strengthening hair fibres: Hair can be damaged in a number of ways including exposure to heat, bleaching, use of shampoos and styling products, brushing and combing, and exposure to the environment, for example ultra-violet light. Existing treatments designed to repair damaged hair make use of surface active materials that mask the problem rather... Agent: Conopco, Inc., D/b/a Unilever
20140335039 - Novel oil-in-water emulsions enriched with salt which are highly viscous and stable over time: Disclosed is a composition in the form of an oil-in-water emulsion, including: 5-55 wt % of an oil phase; 0.025-3.75 wt % of at least one cross-linked anionic polyelectrolyte resulting from the polymerization of partially or completely salified 2-methyl 2-[(1-oxo 2-propenyl)amino]1-propanesulfonic acid, with at least one neutral monomer selected from... Agent: Societe D'exploitation De Produits Pour Les Indus- Tries Chimiques Seppic
20140335040 - Method of providing cleanness to hair and/or scalp: Disclosed is a method of providing cleanness to hair and/or scalp, for example, providing hair volume and/or providing less oiliness on hair and/or scalp, by applying a hair care composition comprising cationic surfactants, high melting point fatty compounds, metal pyrithione, and metal salts other than metal pyrithiones.... Agent: The Procter & Gamble Company
20140335043 - Compositions comprising extracts of bursera simaruba: The present invention relates to a skin care composition comprising an extract of Bursera simaruba seeds and a cosmetically acceptable topical carrier. Such composition is useful for improving skin barrier function and moisturization as well as improving signs of skin aging.... Agent: Johnson & Johnson Consumer Companies, Inc.
20140335044 - Silicone elastomer particle and an aqueous dispersion comprising the same: One of the purposes of the present invention is to provide a silicone elastomer particle and an aqueous dispersion of the silicone elastomer particles, which prevent generation of odor from oxygenation of nonionic surfactants. The present invention provides a silicone elastomer particle having a crosslinking structure formed by an addition... Agent: Shin-etsu Chemical Co., Ltd.
20140335045 - Bfgf-polymer conjugates, methods for making the same and applications thereof: A heparin mimicking polymer, its conjugate with bFGF, and method of making and using the same are disclosed. In particular, described herein are conjugates of biologic agents (e.g., bFGF) and heparin mimicking polymers having superior stability while retaining full native activity after a variety of stressors.... Agent:
20140335046 - Compositions, methods and systems for regenerative cosmetics: A method of inducing or promoting hair growth on the scalp of a subject, comprising the steps of (i) providing an ECM composition including at least one ECM material, (ii) administering inciting event means to a target skin location on the subject to induce an inciting event, and (iii) administering... Agent:
20140335047 - Drug delivery product and methods: The present invention provides a particulate delivery system comprising an extracted yeast cell wall comprising beta-glucan, a payload molecule and a payload trapping molecule. The invention further provides methods of making and methods of using the particulate delivery system.... Agent: University Of Massachusetts
20140335049 - Quil a fraction with low toxicity and use thereof: Fraction A of Quil A can be used together with at least one other adjuvant for the preparation of an adjuvant composition, where the included adjuvant components act synergistically to enhance level of immune response and have synergistic immunomodulating activity on the co-administered antigens or immunogens. Other adjuvants can comprise... Agent:
20140335050 - Methods, compositions, and kits for the treatment of cancer: The invention features methods, compositions, and kits for the administration of an HSP90 inhibitor, OBAA, flunarizine, aphidicolin, damnacanthal, dantrolene, or an analog thereof, alone, or in combination with, e.g., a TAA, an antigen-binding scaffold (e.g., an antibody, a soluble T cell receptor, or a chimeric receptor) specific for a TAA,... Agent: Cytocure LLC
20140335052 - Combination therapy for treating hcv infection in an hcv-hiv coinfected patient population: The present invention relates to therapeutic combinations comprising (a) Compound (1), or a pharmaceutically acceptable salt thereof, as herein described, (b) an interferon alfa and (c) ribavirin. Compound (1) is a selective and potent inhibitor of the HCV NS3 serine protease. The present invention also relates to methods of using... Agent: Boehringer Ingelheim International Gmbh
20140335051 - Synergistic biomolecule-polymer conjugates: The synergistic biomolecule-polymer conjugates are the long-acting, in vivo controlled continuous-release and hybrid synergy systems of biomolecules that provide increased biological activities and enhanced pharmacological properties for achieving greater therapeutic efficacies.... Agent: Peg Biosciences, Inc.
20140335054 - Cns targeting aav vectors and methods of use thereof: The invention in some aspects relates to recombinant adeno-associated viruses useful for targeting transgenes to CNS tissue, and compositions comprising the same, and methods of use thereof. In some aspects, the invention provides methods and compositions for treating CNS-related disorders.... Agent: University Of Massachusetts
20140335053 - Novel mhc class ii restricted t cell epitopes from the cancer antigen, ny eso-1: The present invention discloses the identification and isolation of novel MHC class II epitopes derived from the cancer antigen, NY ESO-1. The novel MHC class II epitopes from NY-EsO-1 are recognized by CD4+ T lymphocytes in an HLA class II restricted manner, in particular HLA-DR or HLA-DP restricted. The products... Agent: The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services
20140335063 - Delivery methods and compositions for nuclease-mediated genome engineering: Disclosed herein are methods and compositions for delivery of engineered nucleases and donor molecules into the genome of a cell.... Agent:
20140335064 - Human skin equivalents expressing exogenous polypeptides: The present invention relates generally to compositions for wound closure. More specifically, the present invention provides human skin equivalents engineered to express exogenous polypeptides (e.g., antimicrobial polypeptides and keratinocyte growth factor 2) and compositions and methods for making human skin equivalents engineered to express exogenous polypeptides. In addition, the present... Agent:
20140335065 - Human milk oligosaccharides for preventing injury and/or promoting healing of the gastrointestinal tract: Disclosed are nutritional compositions including human milk oligosaccharides that can be administered to individuals including preterm infants, infants, toddlers, children, and adults for preventing injury and/or improving the healing of the gastrointestinal tract. Additional suitable methods of using the nutritional compositions including the human milk oligosaccharides are also disclosed.... Agent: Abbott Laboratories
20140335066 - Lactobacillus plantarum inducia dsm 21379 as enhancer of cellular immunity, hypocholesterolemic and anti-oxidative agent and antimicrobial agent against clostridium difficile: A microorganism strain Lactobacillus plantarum Inducia DSM 21379 for use as hypocholesterolemic, antimicrobial and anti-oxidative agent and as enhancer of the natural defense potential of a subject. L. plantarum Inducia is used for reducing the level of LDL-cholesterol in blood for preventing the cholesterol metabolism disorders and cardiovascular disorders. L.... Agent: Tervisliku Piima Biotehnoloogiate Arenduskeskus OÜ (bio-competence Centre Of
20140335058 - Assay for the prediction of therapeutic effectiveness of mesenchymal stromal cells, and methods of using same: The invention relates to assays for testing the therapeutic effectiveness of mesenchymal stromal cell (MSC) populations and methods of treating pathologies with passaged and/or frozen and thawed MSC populations.... Agent: Allocure Inc.
20140335062 - Co-cultured mesenchymal stem cells and myocytes: Co-culturing of mesenchymal stem cells or tissues comprising mesenchymal stem cells with myocytes or myocyte containing tissues provide for the long term culture and expansion of myocytes. The co-culture gives rise to three-dimensional functioning cardiac tissue grafts or constructs.... Agent:
20140335060 - Equine amniotic membrane-derived mesenchymal stem cells: The present invention relates to equine amniotic membrane-derived mesenchymal stem cells (eAM-MSCs) and a preparation method thereof. More specifically, the present invention relates to equine amniotic membrane-derived mesenchymal stem cells, which show negative immunological responses to all of the human markers CD19, CD20, CD28, CD31, CD34, CD38, CD41a, CD62L, CD62P... Agent:
20140335057 - Methods for culturing minimally-passaged fibroblasts and uses thereof: The present invention relates to novel methods of growing at least 100 million minimally-passaged fibroblasts from a small biopsy specimen. The invention includes methods wherein a small biopsy specimen is needed directly into a large tissue culture flask, and passaged so more than three times.... Agent: Fibrocell Technologies, Inc.
20140335055 - Regenerative autologous cell therapies and methods of use: The present novel technology relates to an autologous cell therapy that comprises a pre-determined amount of a processed bone marrow cellular matrix with a pre-determined amount of pre-mixture, where the pre-mixture includes quantities of anticoagulant solution, dextrose and phosphate buffered saline, and methods for production. The present novel technology further... Agent:
20140335059 - Stem cell-derived neural cells for cell therapy in neurological disorders: The present invention provides methods and uses of neural cells differentiated from adult stem cells of the oral mucosa for cell therapy of neurological and psychiatric diseases and disorders. Methods for direction of differentiation of oral mucosal stem cells into neuronal or neuron supporting cells are also provided.... Agent:
20140335061 - Supplemented oil compositions and methods for improved health: Disclosed are compositions and methods comprising supplemented oils for improving health, reducing cardiovascular risk factors, or treating certain conditions.... Agent: Metaproteomics, LLC
20140335056 - Sustained releasing pharmaceutical composition: The present invention relates to a formulation made from a chitosan, a gelatin, and a phosphate salt can provide a sustained release/maintenance of a therapeutic agent, wherein the phosphate salt is selected from the group consisting of disodium phosphate and ammonium hydrogen phosphate.... Agent:
20140335069 - Glucose-6-phosphate dehydrogenase assays: Aspects of embodiments may include methods for automated enzymatic detection of glucose-6-phosphate dehydrogenase (G6PD) activity. Aspects of embodiments may include methods for enzymatic detection of G6PD activity in droplets in oil. Aspects of embodiments may include a system including a droplet actuator. Aspects of embodiments may include a treatment method.... Agent: Advanced Liquid Logic, Inc.
20140335067 - Novel use of ec-sod and method for preparing thereof: A method for treating a disease, particularly asthma and anaphylactic shock, comprises administering to a subject in need thereof an effective amount of an EC-SOD protein or a vector having a polynucleotide encoding thereof.... Agent:
20140335068 - Novel use of ec-sod for treating angiogenesis-mediated eye diseases: A method for treating an angiogenesis-mediated eye disease, includes administering to a subject in need thereof an effective amount of EC-SOD protein, or a vector having a polynucleotide encoding the EC-SOD protein, to treat angiogenesis-mediated eye diseases.... Agent:
20140335070 - Dose escalation enzyme replacement therapy for treating acid sphingomyelinase deficiency: The invention relates to dose escalation enzyme replacement therapy using acid sphingomyelinase (ASM) for the treatment of human subjects having acid sphingomyelinase deficiency (ASMD), and, in particular, patients with non-neurological manifestations of Niemann-Pick Disease (NPD), and in certain embodiments, NPD type B.... Agent: Icahn School Of Medicine At Mount Sinai
20140335071 - Composition exhibiting a von willebrand factor (vwf) protease activity comprising a polypeptide chain with the amino acid sequence aaggilhlellv: The invention relates to vWF cleaving entities having a molecular weight of 180 kD, 170 kD, 160 kD, 120 kD or 110 kD and an N-terminal amino acid sequence of AAGGILHLELLV, vWF cleaving complexes and methods for their production.... Agent: Baxter Innovations Gmbh
20140335072 - Method of treating or reducing efp: The present invention is directed to a method of treating or reducing EFP in a patient comprising administering one or multiple low dose injections of collagenase to an area affected by EFP. The invention encompasses methods wherein the dose of collagenase per injection is between about 50 to about 200... Agent: Auxilium Pharmaceuticals, Inc.
20140335073 - Nutrition for prevention of infections: A nutritional composition comprising a combination of non-digestible oligosaccharides and a product obtained by incubating an aqueous substrate by bifidobacteria and optionally a product obtained by incubating an aqueous substrate by S. thermophilus. Said combination reduces bacterial translocation and improves the intestinal barrier function.... Agent: N.v. Nutricia
20140335074 - Methods for improving medical therapies: Methods are provided herein for enhancing the effectiveness of medical therapies by administering agents that suppress a biological damage response that is inducible by the medical therapy administered to a subject. In certain embodiments, a method is provided for administering an anti-senescent cell agent that suppresses a biological response comprising... Agent:
20140335084 - Antibody formulation: The present invention relates to an anti-CD44 monoclonal antibody formulation, a process for the preparation of said formulation and uses thereof.... Agent: Hoffmann-la Roche Inc.
20140335082 - Combination therapy comprising an mmp-14 binding protein: Proteins that bind to matrix metalloproteinase 14, combination therapies with such proteins and methods of using such proteins are described.... Agent: Dyax Corp.
20140335077 - Compositions and methods for the treatment of cancer using igf-ir antagonists and mapk/erk inhibitors: The present invention relates generally to the field of cancer therapy. More specifically the present invention relates a combination therapy where IGF-1R antagonists are combined with MAPK/ERK pathway inhibitors. The present invention relates to a therapeutic combination comprising an IGF-1R antagonist and a MAPK/ERK pathway inhibitor, and to methods for... Agent:
20140335080 - Ester derivatives of androgen receptor modulators and methods for their use: or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein R1, R2, R3, R4, R5, J1, J2, X, Z, n1 and n2 are as defined herein, and wherein at least one of R1, R2 or R3 is an alkyl, alkenyl, aryl or aralkyl ester, are provided. Uses of such compounds... Agent: British Columbia Cancer Agency Branch
20140335076 - Humanized monoclonal antibodies to hepatocyte growth factor: The present invention is directed toward a humanized neutralizing monoclonal antibody to hepatocyte growth factor, a pharmaceutical composition comprising same, and methods of treatment comprising administering such a pharmaceutical composition to a patient.... Agent: Galaxy Biotech, LLC
20140335075 - Immunoglobulin constant region fc receptor binding agents: IVIG replacement compounds are derived from recombinant and/or biochemical creation of immunologically active biomimetic(s). These replacement compounds are then screened in vitro to assess each replacements compound's efficiency at modulating immune function. Particular replacement compounds are selected for further in vivo validation and dosage/administration optimization. Finally, the replacement compounds are... Agent:
20140335083 - Methods of treatment and prevention of eye diseases: The present invention provides compositions and methods useful for treating and preventing neovascular AMD by inhibition of CCR3. The compositions and methods are useful for treating and preventing diseases and disorders such as but not limited to, neovascular AMD... Agent: Glaxo Group Limited
20140335081 - Treatment for rheumatoid arthritis: Treatment of rheumatoid arthritis (RA) to provide clinical benefit in patients, including decrease in DAS28-CRP by more than 1.2 and/or improvement determined by ACR20, ACR50 or ACR70, comprising administering therapeutic antibody mavrilimumab or other inhibitor targeted to Tyr-Leu-Asp-Phe-Gln motif of granulocyte/macrophage colony stimulating factor receptor alpha (GM-CSFRα). Use of GM-CSFRα... Agent: Medlmmune Limited
20140335078 - Use of complement inhibitors to treat ocular diseases: The present invention relates to the treatment of ocular diseases and conditions by administering a complement pathway inhibitor, particularly an alternative pathway inhibitor. Ocular diseases include age-related macular degeneration, diabetic retinopathy, and ocular angiogenesis. One embodiment comprises the administration of an anti-Factor D antibody in the form of a whole... Agent: Genentech, Inc.
20140335087 - Aspartyl-trna synthetase-fc conjugates: The present invention provides aspartyl-tRNA synthetase and Fc region conjugate polypeptides (DRS-Fc conjugates), such as DRS-Fc fusion proteins, compositions comprising the same, and methods of using such conjugates and compositions for treating or diagnosing a variety of conditions. The DRS-Fc conjugates of the invention have improved controlled release properties, stability,... Agent:
20140335085 - Fusion protein: A new fusion protein which can specifically suppress the autoantibodies, which can effectively prevent or treat the autoimmune disease of autoantibody type, and which can be expressed in an amount sufficient for industrial production. A fusion protein, characterized in that, a protein (X) containing a site recognized by autoantibodies which... Agent: Nihon Pharmaceutical Co., Ltd.
20140335086 - Modified heat shock protein-antigenic peptide complex: The present invention relates to methods for purifying immunogenic, prophylactically and therapeutically effective complexes of modified heat shock proteins noncovalently associated with antigenic peptides of cancer or infected cells. The claimed methods comprise the constructing of a nucleotide sequence encoding a secretable modified heat shock protein, expressing the sequence in... Agent: University Of Miami
20140335088 - Antibodies and vaccines for use in therapeutic and diagnostic methods for alpha-synuclein-related disorders: Methods of treating or delaying onset of a neurodegenerative disorder with α-synuclein pathology in an individual comprise administering an antibody which is produced from a stabilized soluble α-synuclein oligomer and capable of binding a stabilized soluble α-synuclein oligomer, the stabilized soluble α-synuclein oligomer having a lower formation rate to a... Agent:
20140335089 - Antigen-binding molecule for promoting elimination of antigens: The present inventors created antigen-binding molecules containing an antigen-binding domain and an Fcγ-receptor-binding domain, wherein the molecules have human-FcRn-binding activity in an acidic pH range condition, the antigen-binding domain changes the antigen-binding activity of the antigen-binding molecules depending on the ion-concentration condition, and the Fcγ receptor-binding domain has higher binding... Agent: Chugai Seiyaku Kabushiki Kaisha
20140335096 - Anti-glucagon antibodies and uses thereof: Provided are monoclonal antibodies, or antigen-binding fragments thereof, that bind to glucagon. These antibodies are useful in immunoassays of glucagon levels, and/or in vivo, ex vivo or in vitro immunochemical and other imaging methods for detecting glucagon levels, and for diagnostic, prognostic and predictive purposes, and for optimizing therapeutic regimens... Agent:
20140335091 - Anti-glucagon receptor antibodies and methods of use thereof: The present invention provides antagonizing antibodies that bind to glucagon receptor and methods of using same. The anti-glucagon receptor antibodies can be used therapeutically to lower glucose levels in blood, and can be in the prevention and/or treatment of glucose-related disorders, including diabetes, hyperglycemia, hyperinsulinemia, impaired fasting glucose, impaired glucose... Agent: Rinat Neuroscience Corp.
20140335092 - Compositions and methods for immunization against drug resistant acinetobacter baumannii: The present invention provides vaccine compositions comprising OmpA, or antigenic fragments thereof, and related methods of active immunization against A. baumannii infection. The invention also provides antibodies and antigen-binding parts thereof that specifically bind to OmpA, and related methods of passive immunization against A. baumannii infection. The compositions and methods... Agent: Los Angeles Biomedical Research Institute At Harbor-ucla Medical Center
20140335095 - Compositions and methods related to protein a (spa) antibodies as an enhancer of immune response: The present invention concerns methods and compositions for treating or preventing a bacterial infection, particularly infection by a Staphylococcus bacterium. The invention provides methods and compositions for stimulating an immune response against the bacteria. In certain embodiments, the methods and compositions involve a non-toxigenic Protein A (SpA) variant or an... Agent:
20140335097 - Expression vector: The present invention provides an expression vector for cell-surface expression of proteins.... Agent:
20140335094 - Mammalian cytokines; related reagents and methods: Purified genes encoding cytokine from a mammal, reagents related thereto including purified proteins, specific antibodies, and nucleic acids encoding this molecule are provided. Methods of using said reagents and diagnostic kits are also provided.... Agent:
20140335093 - Pd-1 antibodies and pd-l1 antibodies and uses thereof: The invention relates to PD-1 antibodies and PD-L1 antibodies and uses thereof.... Agent: Inserm (institut National De La Sante Et De La Recherche Medicale)
20140335090 - Therapeutic agent for cancer, and method for determining prognosis of cancer: Disclosed are a novel therapeutic agent for cancer such as esophageal squamous cell carcinoma, a method for predicting the prognosis of cancer, and a method for detecting, or predicting the prognosis of, cancer such as esophageal squamous cell carcinoma using a sample that can be collected less invasively. The therapeutic... Agent: Kyoto University
20140335098 - Method of isolating human antibodies: Provided is a novel method of isolating and producing human antibodies with desired specificity from human B cells. In particular, a method of isolating human antibodies from memory B cells obtained from patients which suffer from a disease which is caused by or involves activation of the immune system, for... Agent:
20140335099 - Therapeutic human anti-il-1r1 monoclonal antibody: Antibodies that interact with interleukin-1 receptor type 1 (IL-1R1) are described. Methods of treating IL-1 mediated diseases by administering a pharmaceutically effective amount of antibodies to IL-1R1 are described. Methods of detecting the amount of IL-1R1 in a sample using antibodies to IL-1R1 are described.... Agent: Medarex, L.L.C.
20140335100 - Therapy-enhancing glucan: This invention provides a composition comprising an effective amount of glucan capable of enhancing efficacy of antibodies. This invention further provides the above compositions and a pharmaceutically acceptable carrier. This invention also provides a method for treating a subject with cancer comprising administrating the above-described composition to the subject. This... Agent:
20140335102 - In silico affinity maturation: Methods are disclosed for increasing the binding affinity of binding proteins using in silico affinity maturation.... Agent: Sanofi
20140335101 - Nanobodies against tumor necrosis factor-alpha: The present invention relates to improved Nanobodies™ against Tumor Necrosis Factor-alpha (TNF-alpha), as well as to polypeptides comprising or essentially consisting of one or more of such Nanobodies. The invention also relates to nucleic acids encoding such Nanobodies and polypeptides; to methods for preparing such Nanobodies and polypeptides; to host... Agent: Ablynx N.v.
20140335103 - Cytokine receptors associated with myelogenous haematological proliferative disorders and uses thereof: The disclosure relates to methods and compositions effective in the diagnosis, prognosis and treatment of human hematopoietic cancers. In particular, the disclosure provides tumor-associated genes that encode for cytokine receptors that are differentially expressed in hematopoietic tumor cells of myeloid origin compared with other cells, e.g., normal stem cells.... Agent: Cellerant Therapeutics, Inc.
20140335104 - Methods of detecting cells with a disrupted cell membrane, cells infected with a pathogen, dying cells or dead cells: The present invention relates to methods of modulating the uptake and/or clearance of cells with a disrupted cell membrane, cells infected with a pathogen, dying cells or dead cells, or a portion thereof, which can be used to treat and/or prevent diseases such as cancer, autoimmunity and infections. The present... Agent:
20140335105 - Methods of generating hyper inos expressing cells and uses thereof: A method of generating a hyper iNOS expressing cell includes administering to a myeloid derived cell an amount of a PPARγ agonist and an IL-6/STAT3 signaling pathway antagonist effective to substantially inhibit STAT3 activation in the cell and administering an inflammatory insult to the cell to stimulate hyper iNOS expression... Agent:
20140335106 - Methods and pharmaceutical compositions for treating cancer: A method of treating cancer by inhibiting expression of ubiquitin associated and SH3 domain containing B (UBASH3B) gene or by inhibiting the activity of UBASH3B protein or a functional variant thereof.... Agent:
20140335107 - Anti-cd79b antibodies and immunoconjugates and methods of use: The present invention is directed to compositions of matter useful for the treatment of hematopoietic tumor in mammals and to methods of using those compositions of matter for the same.... Agent: Genentech, Inc.
20140335108 - Utility of insulin-like 6 (insl6) for the treatment of autoimmune diseases: The present invention is directed to compositions and methods to treat an autoimmune disease in a subject, comprising an insulin-like 6 (Insl6) agent, such as an Insl6 polypeptide or variant or fragment thereof, or a nucleic acid encoding Insl6 poly peptide or variant or fragment thereof. Aspects of the present... Agent:
20140335109 - Combination of inotuzumab ozogamicin and torisel for the treatment of cancer: The present invention relates to a therapeutic method for the treatment of cancer that comprises the use of a combination of inotuzumab ozogamicin (CMC-544) and temsirolimus. The enhanced antitumor of the combination therapy is particularly useful for patient population that are recalcitrant to inotuzumab ozogamicin or temsirolimus therapy, relapse after... Agent: Oncology Institute Of Southern Switzerland
20140335110 - Laser-based vaccine adjuvants: The invention is directed to a vaccine for generating an enhanced immune response in a subject previously exposed to non-destructive laser radiation, as compared to an immune response in a subject previously non-exposed to non-destructive laser radiation. The invention is also directed to use of a composition comprising a vaccine... Agent: Ooo "npt Mbp Gormezis"
20140335112 - Novel double-stranded ribonucleic acids with rugged physico-chemical structure and highly specific biologic activity: A novel form of Rugged dsRNA with a unique composition and physical characteristics was identified with high specificity of binding to TLR3, which conveys an important range of therapeutic opportunities. Unlike the previous known antiviral Ampligen® (poly I, poly C12,U) the new and improved form (poly I, poly C30,U) has... Agent: Hemispherx Biopharma, Inc.
20140335111 - Vaccines and immunotherapeutics using il-28 and compositions and methods of using the same: Compositions, recombinant vaccines and live attenuated pathogens comprising one or more isolated nucleic acid molecules that encode an immunogen in combination with an isolated nucleic acid molecule that encodes IL-28 or a functional fragment thereof are disclosed. Methods of inducing an immune response in an individual against an immunogen, using... Agent: The Trustees Of The University Of Pennsylvania
20140335113 - Factor h for transplantation: The present invention provides a method for preventing or inhibiting allograft rejection by a recipient of that allograft by treating the recipient with a composition comprising Factor H (FH). The invention also encompasses methods in which the recipient is also administered one or more immunosuppressants in addition to the Factor... Agent: Baxter International Inc.
20140335114 - Hyr1 as a target for active and passive immunization against candida: The invention features HYR1 as a vaccine target and as a prophylactic strategy for combating disseminated candidiasis.... Agent: Los Angeles Biomedical Research Institute At Harbor-ucla Medical Center
20140335116 - Avoiding narcolepsy risk in influenza vaccines: The invention provides influenza vaccines and methods which improve the safety of influenza vaccines further, in particular in relation to the risk of causing narcolepsy in adjuvanted vaccines.... Agent: Novartis Ag
20140335117 - Identification and attenuation of the immunosuppressive domains in fusion proteins of enveloped rna viruses: The present invention relates to enveloped RNA viruses. The invention in particular relates to the generation of superior antigens for mounting an immune response by first identifying then mutating the immunosuppressive domains in fusion proteins of enveloped RNA viruses resulting in decreased immunosuppressive properties of viral envelope proteins from the... Agent:
20140335115 - Suppressors of mature t cells: Disclosed herein is a viral polypeptide and homologs thereof that inhibit an immune response, particularly the response of memory and effector CD4+ and CD8+ T cells.... Agent: Oregon Health & Science University
20140335118 - Synthetic peptide-based marker vaccine and diagnostic system for effective control of porcine reproductive and respiratory syndrome (prrs): A peptide-based marker vaccine against Porcine Reproductive and Respiratory Syndrome (PRRS) and a set of immunodiagnostic tests for the prevention, monitoring and control of Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) are disclosed. Vaccine formulations according to various embodiments of the invention contain a mixture of peptides derived from PRRSV... Agent: United Biomedical, Inc.
20140335119 - Polypeptide derived from gp41, a vaccine composition comprising said polypeptide, and uses for treating an infection by an hiv virus in an individual: The present invention relates to the field of the in vitro diagnosis of the progression status of an infection of an individual with a virus belonging to the family of the Human Immunodeficiency Viruses (HIV) as well as with the therapeutical treatment of this infectious disease. The invention also relates... Agent: Assistance Publique Hopitaux De Paris
20140335120 - Dual delivery system for heterologous antigens: Provided herein are recombinant Listeria strains expressing a tumor-specific antigenic polypeptide and, optionally, an angiogenic polypeptide wherein a nucleic acid molecule encoding at least one of the polypeptides is operably integrated into the Listeria genome in an open reading frame with a nucleic acid sequence encoding a PEST-containing polypeptide, methods... Agent:
20140335121 - Fimbriae type of prophyromonas gulae: The present inventors found that Porphyromonas gulae is a major pathogen of canine periodontal disease, and demonstrated that the fimA genes encoding FimA (fimbrillin) protein which constitute fimbriae of this bacterium are classified into three major groups, and that each of the groups is correlated with the pathogenicity of this... Agent:
20140335123 - Food composition and uses for diabetes: The present invention provides a composition to promote healthy weight and reduce diabetic complications. The composition provides biologically active ingredients that are combined in a food and provide dietary fiber, trace minerals and phytonutrients, wherein the composition may be used alone or in combination with other foods in a method... Agent:
20140335124 - Recombinant trivalent vaccine against human influenza: Recombinant trivalent vaccine against human influenza contains recombinant adenoviral vector with a nucleotide sequence which encodes at least one antigen of influenza virus strain, while non-replicating nanoparticles are used as adenoviral vectors based on genome of human adenovirus of serotype 5, capable of expressing the haemagglutinin of influenza virus which... Agent:
20140335125 - Attenuated and adapted strain of pseudomonas for delivering antigens: A process for obtaining an adapted strain of Pseudomonas includes the following steps: deleting the genes ExoS, ExoT, aroA and IasI in an initial Pseudomonas strain cultivated in a LB medium; progressively cultivating this strain in a chemically defined medium based on a glucose minimal medium supplemented with magnesium and... Agent: Centre Hospitalier Universitaire Grenoble
20140335126 - V1v2 immunogens: The present invention relates, in general, to human immunodeficiency virus (HIV), and in particular to a vaccine for HIV-1 and to methods of making and using same.... Agent:
20140335127 - System and method for the production of recombinant glycosylated proteins in a prokaryotic host: A system and a method for the production of recombinant N-glycosylated target proteins. The system comprises a prokaryotic organism (e.g. Escherichia coli) into which is introduced a genetic information encoding for a metabolic apparatus capable of carrying out the requested N-glycosylation of the target protein. Said prokaryotic organism also contains... Agent: Eth ZÜ Rich
20140335128 - Adenoviral vector-based malaria vaccines: The invention provides a method of inducing an immune response against malaria in a mammal. The method comprises intramuscularly administering to a mammal a composition comprising a pharmaceutically acceptable carrier and either or both of (a) a first adenoviral vector comprising a nucleic acid sequence encoding a P. falciparum circumsporozoite... Agent:
20140335129 - Non-digestible oligosaccharides for oral induction of tolerance against dietary proteins: Compositions and methods for providing infant nutrition with partially hydrolysed proteins and non-digestible oligosaccharides for use in induction of oral tolerance against native dietary proteins.... Agent: N.v. Nutricia
20140335130 - Amino acid supplementation for a healthy microbiota ecosystem: The present invention pertains to a nutritional composition for reconstituting an optimal healthy microbiota ecosystem in humans or animals. In particular, the present invention relates to an ingestible carrier containing specific amino acids designed to favor the growth of bacteria favorable to individuals health or for reducing the risk of... Agent:
20140335131 - Probiotic prevention and treatment of colon cancer: Methods are provided herein for preventing, delaying the onset of or reducing the progression of colorectal tumorigenesis in a subject identified as at risk of colorectal tumorigenesis, comprising adjusting the composition of gut microbiota in the subject via administering to the subject a composition comprising Bacteroides bacteria or administering to... Agent: California Institute Of Technology
20140335132 - Binding drugs with nanocrystalline cellulose (ncc): This invention describes nanocrystalline cellulose (NCC) for use as a drug delivery excipient. NCC binds significant quantities of water soluble, ionizable drugs, e.g., tetratcycline and doxorubicin, which are released rapidly over a one day period. A surfactant such as cetyl trimethylammonium bromide (CTAB) can bind to the surface of NCC... Agent:
20140335133 - Low-oil pharmaceutical emulsion compositions comprising progestogen: i
20140335134 - Method for treating urinary system disorders: A method for treating urinary system disorders comprising: a pharmaceutical composition comprising a carbon material and a water-containing carrier, the pharmaceutical composition comprising a carbon material in an amount from 0.001 mgs to 100 mgs, both of the carbon material and the water-containing carrier constitute a pharmaceutically acceptable water-containing carrier... Agent:
20140335135 - Pharmaceutical composition: Sustained release formulations of triptorelin are provided.... Agent: Ferring Bv
20140335136 - Compositions for minimizing skin imperfections: Disclosed herein are compositions comprising, in a cosmetically acceptable medium, a silicone material comprising concave and/or annular particles; hydrophobic silica aerogel particles; fillers chosen from platelet type fillers and silica particles other than hydrophobic silica aerogel particles; a fatty substance chosen from fatty alcohols and fatty acids; an emulsifying agent... Agent:
20140335139 - Long lasting breath mint: A long lasting breath mint including a carrier and a flavorant, wherein the carrier includes at least one of a high viscosity cellulose ether and a low viscosity cellulose either and an alginate. The carrier forms a gel upon contact with saliva. A tablet is placed in the mouth of... Agent:
20140335138 - Microcapsules comprising black pigments: Monolayered microcapsules comprising a black pigment and cosmetic formulations comprising them are provided for use particularly in mascara and eye liner formulations. The black pigment may be carbon black, black iron oxide, or both.... Agent:
20140335137 - Topical dna repair composition: Provided herein are topical compositions for repairing sun damaged skin and topical sunscreen compositions for both preventing and repairing sun damage.... Agent:
20140335140 - Natural volatile plant oils to repel arthropods: A composition and method for the controlled release of natural plant oils (essential oils) from a wax matrix to repel insects, arachnids, and other arthropods.... Agent: Verutek Technologies, Inc.
20140335141 - Layered manufacturing utilizing foam as a support and multifunctional material for the creation of parts and for tissue engineering: One aspect of the invention provides a solid freeform fabrication method of creating a three-dimensional article built at least in part from scaffolding layers. The method includes: providing a scaffolding material; providing a supporting material in a shape of a foamy layer; and contacting the scaffolding material with the foamy... Agent:
20140335145 - Biomaterials and implants for enhanced cartilage formation, and methods for making and using them: The invention provides products of manufacture, e.g., biomaterials and implants, for cartilage maintenance and/or formation in-vivo, in-vitro, and ex-vivo, using nanotechnology, e.g., using nanotube, nanowire, nanopillar and/or nanodepots configured on surface structures of the products of manufacture.... Agent:
20140335142 - Method of surface treatment of an implant, an implant treated by said method and an electrolyte solution for use in said method: A method of surface treatment of at least part of an electro-conductive surface of an implant, in particular an orthopaedic or a dental implant is described which permits the simultaneous, electrochemical deposition of a therapeutic agent and a calcium phosphate coating in a combined single-step deposition process. The method involves... Agent: Smith & Nephew Orthopaedics Ag
20140335143 - Polymer blends for drug delivery stent matrix with improved thermal stability: Various embodiments of the present invention generally relate to a polymer blend composition used for coating a medical device that exhibits improved thermal stability. The invention also encompasses implantable medical devices coated the aforementioned coating.... Agent: Abbott Cardiovascular Systems Inc.
20140335144 - Tissue scaffolds derived from forestomach extracellular matrix: The present invention pertains to the development of Extracellular Matrix (ECM) scaffolds derived from the forestomach of a ruminant. Such scaffolds are useful in many clinical and therapeutic applications, including wound repair, tissue regeneration, and breast reconstruction. In addition, the present invention features methods of isolating ECM scaffolds from mammalian... Agent: Mesynthes Ltd.
20140335146 - Growth factor anchoring type bone graft material, method for producing growth factor anchoring type bone graft material, kit for producing growth factor anchoring type bone graft material, and method for forming bone: Provided is a growth factor anchoring type bone graft material, wherein a bone graft substrate exposing at least a collagen fiber is bound to a collagen-binding-site-containing growth factor which contains a growth factor receptor agonist peptide and a collagen-binding peptide. The same can be produced by mixing a bone graft... Agent: School Juridical Person Kitasato Institute
20140335147 - Regeneration aid for bone defects: The invention relates to a molded part for supporting bone regeneration, in particular the regeneration of a jawbone or jawbone section in a mammal, preferably a human, wherein the molded part is suitable for applying to the jawbone and has a coating having a composition comprising at least one collagen,... Agent:
20140335148 - Bioactive substance-containing nanofibers and uses thereof: An ultrafine fiber comprises a ceramic-based fibrous body and a biologically active substance encapsulated in the body, substantially encapsulated in the body, or surface-attached to the body. In an example, an ultrafine fiber comprises a core comprising a biologically active substance and a ceramic-based shell surrounding or substantially surrounding the... Agent:
20140335149 - Wound-healing promoting material: The object of the present invention is to provide a means for utilizing cells that have effects on wound healing as wound-healing promoting materials by efficiently concentrating such cells within a short period of time. The present invention provides a wound-healing promoting material which comprises a sheet-like porous body having... Agent:
20140335150 - Therapeutic patch: The invention relates to a topical patch comprising a therapeutic compound-impermeable backing layer, a self-adhesive matrix based on polysiloxanes and containing capsaicin or a therapeutic compound analogous to capsaicin, and a protective film to be removed before use, in which the matrix contains liquid microreservoirs based on an amphiphilic solvent,... Agent:
20140335151 - Patch containing non-steroidal anti-inflammatory drug: The present invention is directed to a patch containing a non-steroidal anti-inflammatory drug including an adhesive layer composed of a transdermal preparation on a support, the transdermal preparation including a) 10 to 40% by weight of a non-aqueous base material based on the total weight of the transdermal preparation, b)... Agent:
20140335159 - Biodegradable nanoparticles as novel hemoglobin-based oxygen carriers and methods of using the same: Compositions of matter and methods for making, storing and administering artificial blood substitutes. Artificial blood substitutes may have oxygen carriers that encapsulate an oxygen-binding compound in a polymer vesicle. Oxygen-binding compounds may include hemoglobin, myoglobin, or other oxygen binding compounds having characteristics similar to hemoglobin. Oxygen carriers may include nanoparticles,... Agent:
20140335160 - Biodegradable nanoparticles as novel hemoglobin-based oxygen carriers and methods of using the same: Compositions of matter and methods for making, storing and administering artificial blood substitutes. Artificial blood substitutes may have oxygen carriers that encapsulate an oxygen-binding compound in a polymer vesicle. Oxygen-binding compounds may include hemoglobin, myoglobin, or other oxygen binding compounds having characteristics similar to hemoglobin. Oxygen carriers may include nanoparticles,... Agent:
20140335157 - Cationic lipid having improved intracellular kinetics: m
20140335155 - Composition for improving skin conditions, containing extracellular domain of human bone morphogenetic protein receptor 1a as active ingredient: The present invention provides a composition for improving skin conditions, containing the extracellular domain of human bone morphogenetic protein receptor 1a as an active ingredient. The present invention contains the extracellular domain of human bone morphogenetic protein receptor 1a as an active ingredient inside a nanoliposome comprising hydrogenated lecithin as... Agent: Joint Center For Biosceinces
20140335161 - Compositions and methods for the diagnosis and therapy of bcl2-associated cancers: Provided are methods and compositions for the treatment of cancers associated with overexpression of a BCL2 gene and/or gene product in a subject, and methods and compositions for the improvement of anti-cancer therapy, such as chemotherapy and radiation therapy. Also provided are methods for determining the efficacy of a cancer... Agent: The Ohio State University Research Foundation
20140335164 - Liposomes and its production method: The developed method combines the ability of liposomes in the transport and release of drugs and the specific expression of folic acid receptor on the surface of cell membranes that allow transmembrane transport mediated by specific liposomes. Thus allows the transport of therapeutic agents and/or imaging agents, which are inside... Agent: Universidade Do Minho
20140335152 - Methods and compositions for enhancing the uptake of therapeutic agents by target cells: The present invention relates to a new use of a known medicament. Specifically, the invention relates to methods and compositions for enhancing the therapeutic efficacy of a therapeutic agent by increasing the uptake of the therapeutic agent by target cells, and in particular relates to a pharmaceutical composition comprising a... Agent: Beijing Protgen Ltd.
20140335154 - Methods and formulations to achieve tumor targeted double stranded rna mediated cell death: A composition having double stranded ribonucleic acid (dsRNA) molecules is provided. The composition induces tumor cell death or suppresses tumor growth. The double stranded RNA molecules contain equal to or less than 15 base pairs. Methods for delivery of the composition are also disclosed.... Agent: Multicell Immunotherapeutics, Inc.
20140335156 - Nanoparticle-assisted ultrasound for cancer therapy: Methods for killing cancer cells and treating cancer in a subject by exposing the cells to nanoparticles, and irradiating with a focused, low to medium power ultrasound. The nanoparticles can be gold, iron oxide, copper, silver, polystyrene, PEG, or liposome nanoparticles. The nanoparticles can have a cancer drug attached, such... Agent: Academia Sinica
20140335162 - Pharmaceutical composition for treatment of allergic reactions: The invention relates to a pharmaceutical composition made of one or more preparations and comprising a physiologically effective dose of at least one IL-4 and/or IL-13 inhibitor and at least one allergene, and a matrix, wherein at least the inhibitor is solved or embedded, or whereon at least the inhibitor... Agent:
20140335158 - Protein and nucleic acid delivery vehicles, components and mechanisms thereof: Complex viruses are assembled from simple protein subunits by sequential and irreversible assembly. During genome packaging in bacteriophages, a powerful molecular motor assembles at the special portal vertex of an empty prohead to initiate packaging. An aspect of the invention relates to the phage T4 packaging machine being highly promiscuous,... Agent:
20140335165 - Sustained-release nucleic acid matrix compositions: There are provided compositions for extended release of a nucleic acid agent, comprising a lipid-saturated matrix formed with a biodegradable polymer. Also provided are methods of producing the matrix compositions and methods for using the matrix compositions to provide controlled release of the nucleic acid agent.... Agent:
20140335163 - Targeted iduronate-2-sulfatase compounds: The present invention is related to a compound that includes a lysosomal enzyme and a targeting moiety, for example, where compound is a fusion protein including iduronate-2-sulfatase and Angiopep-2. In certain embodiments, these compounds, owning to the presence of the targeting moiety can crossing the blood-brain barrier or accumulate in... Agent:
20140335153 - Thin film with high load of active ingredient: A method of preparing a thin film, the method comprising: (a) mixing a lipid, emulsifier, and solvent to provide a uniform first mixture; (b) contacting an active ingredient with the uniform first mixture to provide a thickened second mixture; (c) contacting a binder with the thickened second mixture to provide... Agent: Cure Pharmaceutical Corporation
20140335167 - Consumer products comprising silane-modified oils: A consumer product comprises silane-modified oil comprising a hydrocarbon chain selected from the group consisting of: a saturated oil, an unsaturated oil, and mixtures thereof; and at least one hydrolysable silyl group covalently bonded to the hydrocarbon chain. The silane-modified oil is substantially stripped of substantially stripped of reagents prior... Agent: The Procter & Gamble Company
20140335166 - Methods of making and using nano scale particles: A method for preparing a phospholipid delivery system encapsulating one or more bio-affecting compounds, includes the steps of solubilizing a heterogeneous phospholipid mixture into an organic solvent to form a concentrated formulation of phospholipids, in which the phospholipids include a charged phospholipid species and mixing the concentrated formulation with an... Agent:
20140335168 - Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device: Embodiments of the invention provide swallowable devices, preparations and methods for delivering drugs and other therapeutic agents within the GI tract. Many embodiments provide a swallowable device for delivering the agents. Particular embodiments provide a swallowable device such as a capsule for delivering drugs into the intestinal wall or other... Agent: Rani Therapeutics, LLC
20140335169 - Peptide pharmaceutical for oral delivery: Acid-containing oral pharmaceutical compositions are provided wherein the pharmaceutical active agents are peptide compounds (i.e., those that include a plurality of amino acids and at least one peptide bond in their molecular structures). Certain barrier layers and/or particulate coated acid are used to reduce any adverse interactions that might otherwise... Agent: Enteris Biopharma, Inc.
20140335170 - Reduced mass metformin formulations: The present invention relates to metformin extended release (XR) formulations with improved compactability to provide reduced mass tablets, granulations, and capsules.... Agent: Bristol-myers Squibb Company
20140335171 - Stable formulations of antiplatelet agents, omega-3 fatty acids and amylose in soft gelatin capsules: The invention discloses stable formulations of acetylsalicylic acid or salts thereof, omega-3 fatty acids and amylose in soft gelatin capsules.... Agent:
20140335172 - Ophthalmological rinsing agent and methods therefof: Disclosed herein is a novel rinsing agent, which may be suitable for use in surgical, and, in particular, ophthalmological procedures. The rinsing agent may by employed to remove emulsified oil droplets from the eye cavity. Also disclosed is a method for effectively removing emulsified silicone oil droplets remaining in the... Agent: The University Of Hong Kong
20140335173 - Release capsules, manufacture and uses thereof: The present invention relates to novel release capsules, particularly for protecting moisture-sensitive materials, particularly compositions for production of chlorine dioxide. The invention also relates to methods of manufacture of such release capsules, uses of such release capsules, and products comprising them.... Agent:
20140335176 - Disintegrant-free delayed release doxylamine and pyridoxine formulation and process of manufacturing: The present invention relates to a delayed release pharmaceutical composition containing doxylamine succinate and pyridoxine HCl for treatment of nausea and vomiting during pregnancy. More specifically, the present invention concerns a disintegrant-free delayed release pharmaceutical composition for oral administration comprising a core and an enteric coating, wherein said core comprising:... Agent:
20140335174 - Dry-coated tablet containing tegafur, gimeracil and oteracil potassium: The present invention provides a dry-coated tablet comprising: an inner core containing, as active ingredients, (a) tegafur, (b) gimeracil, and (c) oteracil potassium; and an outer shell.... Agent: Taiho Pharmaceutical Co., Ltd.
20140335175 - Extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof: An extended release tablet formulation comprising pramipexole or a pharmaceutically acceptable salt thereof in a matrix comprising at least one water swelling polymer other than pregelatinized starch.... Agent: Boehringer Ingelheim International Gmbh
20140335177 - Pharmaceutical composition: Oral pharmaceutical formulations containing ditosylate salts of 4-quinazolineamines are described as well as methods of using the same in the treatment of disorders characterized by aberrant erbB family PTK activity.... Agent:
20140335178 - Dosage forms of apixaban: The present invention relates to a Factor Xa inhibitor dosage form comprising apixaban in a solubility-improved form wherein the dosage form provides controlled release of apixaban and methods for preventing or treating venous thromboembolisms, deep vein thrombosis and acute coronary syndrome with said dosage form.... Agent: Pfizer Inc.
20140335179 - Micronized crystals of atorvastatin hemicalcium: The present invention relates to micronized crystals of atorvastatin hemi-calcium, a method for the preparation of micronized crystals of atorvastatin hemi-calcium and a pharmaceutical dosage form comprising said micronized crystals of atorvastatin hemi-calcium.... Agent: Dsm Sinochem Pharmaceuticals Netherlands B.v.
20140335180 - Products for oral administration comprising extracts of punica granatum (pomegranate), intended for a pet, and applications of same: The invention relates to a product for oral administration intended for a pet, comprising extracts of punica granatum (pomegranate). The invention is characterised in that the invention further comprises at least two additional antioxidant compounds chosen from:— soya isoflavone extracts;— L-carnitine; and— taurine.... Agent: Virbac Sa
20140335182 - Aqueous polymer dispersion based on n,n-diethylaminoethyl methacrylate, its preparation and use: The present invention relates to a process for preparing an aqueous polymer dispersion by free-radical emulsion polymerization of a monomer mixture which comprises N,N-diethylaminoethyl methacrylate, to the polymer dispersion obtainable by this process, and to the use thereof.... Agent:
20140335181 - Dry coated tablet: Provided is a dry coated tablet showing high stability of the active ingredient (proton pump inhibitor, acetylsalicylic acid), which stably and rapidly expresses the pharmacological effect of the active ingredient after administration. A dry coated tablet having an inner core and an outer layer, wherein the inner core is an... Agent:
20140335183 - Wound healing profile: The present invention relates to compositions and methods for tissue regeneration, particularly for treating skin lesions such as wounds. In one aspect, the invention provides wound healing composition characterised by the higher expression levels of phenotypic marker genes such as apolipoprotein D, matrix metalloprotease (2), collagen 3a1 and smooth muscle... Agent: Smith & Nephew, Inc.
20140335187 - Compositions and methods for decreasing the effects of alcohol: The present invention relates probiotic compositions useful in accelerating alcohol catabolism in a subject.... Agent: Biowish Technologies, Inc.
20140335188 - Cosmetic preparation comprising pulverized hydrophobic substances: A substance, which is in principle insoluble in a cosmetic or dermatological preparation, is converted into a powdery product by absorption onto a carrier, wherein said powdery product can be distributed better in the preparation. The preparations comprise water and one or more hydrophobic substances or substance mixtures which are... Agent:
20140335189 - Intestinal peptide targeting ligands: Peptide ligands for transporting therapeutic agents across the intestinal epithelial barrier that ordinarily are inadequately absorbed and must be delivered by alternative means, which contain an isolated amino acid sequence wherein at least one pair of amino acids are of an opposite charge and the pair members are separated by... Agent:
20140335186 - Methods and compositions for enhancing cd4+ regulatory t cells: Disclosed are methods and related compositions for administering immunosuppressants and therapeutic macromolecules for enhancing CD4+ regulatory T cells.... Agent: Selecta Biosciences, Inc.
20140335184 - Nanoparticle assembly, preparation thereof, and active material delivering composite comprising the same: Provided are a nanoparticle assembly including a DNA hydrogel and gold nanoparticles, methods of preparing thereof, and an active material delivering composite including the same. The nanoparticle assembly has an excellent biocompatibility, an ability to prevent an accumulation of the nanoparticle assembly in a body, and is capable of being... Agent: Samsung Electronics Co., Ltd.
20140335185 - Novel microcarrier beads: The invention relates to a novel microcarrier bead; a method for producing same; a therapeutic comprising said microcarrier bead and attached thereto or grown thereon at least one selected cell or tissue type; a method for making said therapeutic; and a method of treatment involving the use of said microcarrier... Agent: National University Of Singapore
20140335191 - Compositions and methods for enhancing brain function: Compositions and methods are provided that enhance cognition in a human to which the composition is orally administered. Remarkably, clinical studies have proven that contemplated compositions achieved the desired effects using a minimal number of active ingredients at or near threshold active dosages, wherein such compositions almost exclusively comprise huperzine... Agent:
20140335190 - New non-abusable pharmaceutical composition comprising opioids: There is provided pharmaceutical compositions for the treatment of pain comprising a pharmacologically-effective amount of an opioid analgesic, or a pharmaceutically-acceptable salt thereof, presented in particulate form upon the surfaces of carrier particles comprising a pharmacologically-effective amount of an opioid antagonist, or a pharmaceutically-acceptable salt thereof, which carrier particles are... Agent:
20140335192 - Delivery of rna interfering agents: Provided are compositions for the delivery of biomolecules, such as nucleic acids into target cells, and methods of making and using same. The compositions comprise nucleic acid delivery complexes that include a nucleic acid, such as an RNA interfering agent, an RNA neutralization domain, a double stranded RNA binding domain,... Agent:
20140335193 - Controlled-release injectable microparticle: The invention relates to a controlled-release injectable microparticle comprising a polyvinyl alcohol polymer and one or more hormones, in particular progesterone. Said microparticle induces estrus in female mammals after a single application. The invention also relates to a method for obtaining the microparticle.... Agent: Unl Universidad Nacional Del Litoral
20140335194 - Polymeric nanoparticle solution composition and its manufacturing process: Disclosed are a polymeric drug carrier-containing pharmaceutical composition with enhanced stability in its solution state and a method for stabilizing the same. More particularly, disclosed are a pharmaceutical aqueous solution composition for storage under refrigeration containing a polymeric drug carrier comprising an amphiphilic block copolymer comprised of a hydrophilic block... Agent:
20140335195 - Platelet lysate gel: The invention concerns a pharmaceutical composition comprising a platelet lysate and its use to treat a wound, an anal fissure, vaginal atrophy or a wrinkle.... Agent: Cell Therapy Limited
20140335196 - Fungicidal compositions: The present invention relates to fungicidal compositions and particularly fungicidal compositions comprising anhydrous milk fat (AMF), soybean oil and/or coconut fat. The invention also relates to a fungicidal method employing a composition of the invention. The compositions and methods of the invention have applications in the management (prevention and control)... Agent: The New Zealand Institute For Plant And Food Research Limited
20140335197 - Combustion synthesis of calcium phosphate constructs and powders doped with atoms, molecules, ions, or compounds: The invention relates to a synthetic bone material and a process for making the same. The synthetic bone material may comprise multiple phases of calcium phosphate. Another aspect of the invention is a porous filter, and the method of making the same, and wherein the porous filter is substantially similar... Agent:
20140335198 - Stable bicarbonate ion-containing drug solution: The invention relates to a stable bicarbonate ion-containing drug solution, particularly a bicarbonate-containing drug solution for dialysis in which the stability has been improved by the presence of a phosphate ion. Further, the invention relates to a drug solution for acute blood purification, particularly a dialysate and a substitution liquid... Agent: Fuso Pharmaceutical Industries, Ltd.
20140335199 - Peroxycarboxylic acid compositions suitable for inline optical or conductivity monitoring: Peracid stable fluorescent active compounds in highly acidic, equilibrium peroxycarboxylic acid sanitizing compositions are disclosed as having improved fluorescent stability allowing for monitoring of peroxycarboxylic acid concentration by conductivity and/or optical sensors. Beneficially, the compositions are also low odor and low/no VOC dual functioning acid wash and sanitizing compositions.... Agent:
20140335200 - Method of preparing silver loaded activated carbon fiber: A method of preparing a silver loaded activated carbon fiber includes the following steps. A viscose fiber is treated with a hydroxyalkyl cyclodextrin aqueous solution to obtain a hydroxyalkyl cyclodextrin loaded viscose fiber. The hydroxyalkyl cyclodextrin loaded viscose fiber is then treated with a silver salt aqueous solution to obtain... Agent: Zhangjiagang Nellnano Technology Co., Ltd.
20140335201 - Fungicidal compositions: The present invention provides a composition comprising a combination of components A) and B), wherein component A) is a compound of formula (I) and the component (B) is a further fungicide, insecticide or herbicide.... Agent: Syngenta Participations Ag
20140335202 - Iron sulfate-based phosphate adsorbent: The present invention relates to a process for the preparation of a novel composition, and to the use of the composition as a phosphate adsorbent, in particular for administration in humans or animals.... Agent:
20140335203 - Synergistic blends of antimicrobials useful for controlling microorganisms in industrial processes: The present invention provides a method of controlling bacterial contamination using synergistic interactions of antimicrobials. The invention consists of combinations of chlorine dioxide and organic acid whose combined antimicrobial effect is greater than the sum of their individual activities, i.e., synergistic.... Agent: Hercules Incorporated
20140335204 - Synergistic blends of antimicrobials useful for controlling microorganisms in industrial processes: The present invention provides a method of controlling bacterial contamination using synergistic interactions of antimicrobials. The invention consists of combinations of chlorine dioxide and organic acid whose combined antimicrobial effect is greater than the sum of their individual activities, i.e., synergistic.... Agent: Hercules Incorporated
20140335205 - Materials and methods for treatment of disorders associated with oxidative stress: The subject invention pertains to materials and methods for the prevention and treatment of disease conditions associated with oxidative stress or a compromised reducing environment, including inflammatory bowel diseases such as Crohn's disease and ulcerative colitis. Therapeutic compositions of the invention include compositions that can neutralize hydrogen peroxide, such as... Agent:
20140335206 - Topical analgesic composition: This invention concerns a synergistic combination of a topical anesthetic and wound barrier forming agent capable of providing extended analgesia of ‘significant open wounds’ (that being, for example, a laceration, surgical incision, abrasion, ulcer or burn, but not being a minor cut, scratch, sting, burn or abrasion) in which conventional... Agent:
20140335207 - Deep topical systemic nitric oxide therapy apparatus and method: A topical mixture that produces nitric oxide and a method for using the topical mixture to increase the vasodilation of a bloodstream via transdermal absorption of the nitric oxide. The nitric oxide can then affect subcutaneous tissues. The systemic vasodilation of a mammal may be increased via a topical application... Agent:
20140335208 - Tetrahydrocannabivarin (thcv) for use in the protection of pancreatic islet cells: The present invention relates to the phytocannabinoid tetrahydrocannabivarin (THCV) for use in the protection of pancreatic islet cells. Preferably the pancreatic islet cells to be protected are beta cells. More preferably the protection of the pancreatic islet cells maintains insulin production at levels which are able to substantially control or... Agent:
20140335209 - Pawpaw and/or peach derived composition: There is provided a process for making a composition suitable for topical application comprising the steps of a) heating at least one fruit and/or vegetable pulp to up to a temperature in the range of about 40° C. to 100° C.; b) mixing between 1 and 40% w/w of a... Agent:
20140335210 - Method and agrochemical composition for using larch wood extracts in agriculture: A method of using larch wood extracts as natural compounds to give superior resistance to plants, plant parts, fruits and/or flowers against pathogens as bacteria and fungi. The method includes using larch wood extracts as natural compounds that naturally protect plant tissues against ultraviolet radiation and temperature, thus giving protection... Agent: Flavitpure, Inc.
20140335211 - Use of neohesperidin: The present invention discloses a use of neohesperidin or a neohesperidin-containing plant extract in the manufacture of a product for improving and/or promoting skin microcirculation, or for eliminating and/or alleviating diseases or conditions associated with poor skin microcirculation. The present invention also discloses a composition comprising an effective amount of... Agent: Natural Medicine Institute Of Zhejiang Yangshengtang Co., LtdPrevious industry: Chemistry of inorganic compounds
Next industry: Plastic article or earthenware shaping or treating: apparatus
RSS FEED for 20141113:
Integrate FreshPatents.com into your RSS reader/aggregator or website to track weekly updates.
For more info, read this article.
Thank you for viewing Drug, bio-affecting and body treating compositions patents on the FreshPatents.com website. These are patent applications which have been filed in the United States. There are a variety ways to browse Drug, bio-affecting and body treating compositions patent applications on our website including browsing by date, agent, inventor, and industry. If you are interested in receiving occasional emails regarding Drug, bio-affecting and body treating compositions patents we recommend signing up for free keyword monitoring by email.
Results in 0.8222 seconds